1. Home
  2. MBWM vs GYRE Comparison

MBWM vs GYRE Comparison

Compare MBWM & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mercantile Bank Corporation

MBWM

Mercantile Bank Corporation

HOLD

Current Price

$50.23

Market Cap

863.0M

Sector

Finance

ML Signal

HOLD

Logo Gyre Therapeutics Inc.

GYRE

Gyre Therapeutics Inc.

HOLD

Current Price

$7.72

Market Cap

759.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MBWM
GYRE
Founded
1997
2002
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
863.0M
759.1M
IPO Year
1997
2004

Fundamental Metrics

Financial Performance
Metric
MBWM
GYRE
Price
$50.23
$7.72
Analyst Decision
Buy
Strong Buy
Analyst Count
4
2
Target Price
$53.63
$17.00
AVG Volume (30 Days)
77.9K
78.0K
Earning Date
04-21-2026
01-01-0001
Dividend Yield
3.00%
N/A
EPS Growth
10.95
103.55
EPS
5.47
0.04
Revenue
N/A
$275,000.00
Revenue This Year
$20.28
$11.59
Revenue Next Year
$4.67
$26.31
P/E Ratio
$9.49
$194.75
Revenue Growth
N/A
N/A
52 Week Low
$37.76
$6.11
52 Week High
$55.77
$12.62

Technical Indicators

Market Signals
Indicator
MBWM
GYRE
Relative Strength Index (RSI) 38.11 44.69
Support Level $49.95 $7.10
Resistance Level $50.36 $8.25
Average True Range (ATR) 1.73 0.58
MACD -0.42 -0.07
Stochastic Oscillator 27.81 9.55

Price Performance

Historical Comparison
MBWM
GYRE

About MBWM Mercantile Bank Corporation

Mercantile Bank Corp operates as a bank holding company. It offers various commercial banking services to individuals, businesses, governmental units, and other institutions. These services include deposit products such as checking, savings, and term certificate accounts and lending products such as commercial, residential mortgage, and installment loans. The company generates revenue from interest and dividends earned on loans, securities, and other financial instruments.

About GYRE Gyre Therapeutics Inc.

Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.

Share on Social Networks: